Literature DB >> 6285432

Role of beta-adrenergic receptors in the antidepressant activity of alprazolam.

V H Sethy, D H Hodges.   

Abstract

Chronic intravenous infusion of reserpine significantly increased beta-adrenergic receptors (beta-AR) in the cerebra cortex of rats. This increase in beta-AR is partially blocked by chronic treatment with alprazolam. However, similar effects were not observed with diazepam. These results indicate that beta-AR may be involved in the antidepressant activity of alprazolam.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285432

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  6 in total

Review 1.  Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system.

Authors:  G B Baker; A J Greenshaw
Journal:  Cell Mol Neurobiol       Date:  1989-03       Impact factor: 5.046

2.  Regulation of serotonin type 2 (5-HT2) and beta-adrenergic receptors in rat cerebral cortex following novel and classical antidepressant treatment.

Authors:  F Lafaille; S A Welner; B E Suranyi-Cadotte
Journal:  J Psychiatry Neurosci       Date:  1991-11       Impact factor: 6.186

3.  Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorder.

Authors:  J D Amsterdam; M Kaplan; L Potter; L Bloom; K Rickels
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Effects of subchronic administration of antidepressants and anxiolytics on levels of the alpha subunits of G proteins in the rat brain.

Authors:  Y Dwivedi; G N Pandey
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 5.  Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression.

Authors:  G W Dawson; S G Jue; R N Brogden
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

6.  GABAergic effects of reserpine following chronic treatment.

Authors:  P D Suzdak; G Gianutsos
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.